2023-08-012024-07-312024-07-31false10867416PHARMAMEDICAL LTD2025-03-26falseiso4217:GBPxbrli:pure108674162023-08-01108674162024-07-31108674162023-08-012024-07-31108674162022-08-01108674162023-07-31108674162022-08-012023-07-3110867416bus:SmallEntities2023-08-012024-07-3110867416bus:AuditExempt-NoAccountantsReport2023-08-012024-07-3110867416bus:FullAccounts2023-08-012024-07-3110867416bus:PrivateLimitedCompanyLtd2023-08-012024-07-3110867416core:WithinOneYear2024-07-3110867416core:AfterOneYear2024-07-3110867416core:WithinOneYear2023-07-3110867416core:AfterOneYear2023-07-3110867416core:ShareCapital2024-07-3110867416core:SharePremium2024-07-3110867416core:RevaluationReserve2024-07-3110867416core:OtherReservesSubtotal2024-07-3110867416core:RetainedEarningsAccumulatedLosses2024-07-3110867416core:ShareCapital2023-07-3110867416core:SharePremium2023-07-3110867416core:RevaluationReserve2023-07-3110867416core:OtherReservesSubtotal2023-07-3110867416core:RetainedEarningsAccumulatedLosses2023-07-3110867416core:LandBuildings2024-07-3110867416core:PlantMachinery2024-07-3110867416core:Vehicles2024-07-3110867416core:FurnitureFittings2024-07-3110867416core:OfficeEquipment2024-07-3110867416core:NetGoodwill2024-07-3110867416core:IntangibleAssetsOtherThanGoodwill2024-07-3110867416core:ListedExchangeTraded2024-07-3110867416core:UnlistedNon-exchangeTraded2024-07-3110867416core:LandBuildings2023-07-3110867416core:PlantMachinery2023-07-3110867416core:Vehicles2023-07-3110867416core:FurnitureFittings2023-07-3110867416core:OfficeEquipment2023-07-3110867416core:NetGoodwill2023-07-3110867416core:IntangibleAssetsOtherThanGoodwill2023-07-3110867416core:ListedExchangeTraded2023-07-3110867416core:UnlistedNon-exchangeTraded2023-07-3110867416core:LandBuildings2023-08-012024-07-3110867416core:PlantMachinery2023-08-012024-07-3110867416core:Vehicles2023-08-012024-07-3110867416core:FurnitureFittings2023-08-012024-07-3110867416core:OfficeEquipment2023-08-012024-07-3110867416core:NetGoodwill2023-08-012024-07-3110867416core:IntangibleAssetsOtherThanGoodwill2023-08-012024-07-3110867416core:ListedExchangeTraded2023-08-012024-07-3110867416core:UnlistedNon-exchangeTraded2023-08-012024-07-3110867416core:MoreThanFiveYears2023-08-012024-07-3110867416core:Non-currentFinancialInstruments2024-07-3110867416core:Non-currentFinancialInstruments2023-07-3110867416dpl:CostSales2023-08-012024-07-3110867416dpl:DistributionCosts2023-08-012024-07-3110867416core:LandBuildings2023-08-012024-07-3110867416core:PlantMachinery2023-08-012024-07-3110867416core:Vehicles2023-08-012024-07-3110867416core:FurnitureFittings2023-08-012024-07-3110867416core:OfficeEquipment2023-08-012024-07-3110867416dpl:AdministrativeExpenses2023-08-012024-07-3110867416core:NetGoodwill2023-08-012024-07-3110867416core:IntangibleAssetsOtherThanGoodwill2023-08-012024-07-3110867416dpl:GroupUndertakings2023-08-012024-07-3110867416dpl:ParticipatingInterests2023-08-012024-07-3110867416dpl:GroupUndertakingscore:ListedExchangeTraded2023-08-012024-07-3110867416core:ListedExchangeTraded2023-08-012024-07-3110867416dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-08-012024-07-3110867416core:UnlistedNon-exchangeTraded2023-08-012024-07-3110867416dpl:CostSales2022-08-012023-07-3110867416dpl:DistributionCosts2022-08-012023-07-3110867416core:LandBuildings2022-08-012023-07-3110867416core:PlantMachinery2022-08-012023-07-3110867416core:Vehicles2022-08-012023-07-3110867416core:FurnitureFittings2022-08-012023-07-3110867416core:OfficeEquipment2022-08-012023-07-3110867416dpl:AdministrativeExpenses2022-08-012023-07-3110867416core:NetGoodwill2022-08-012023-07-3110867416core:IntangibleAssetsOtherThanGoodwill2022-08-012023-07-3110867416dpl:GroupUndertakings2022-08-012023-07-3110867416dpl:ParticipatingInterests2022-08-012023-07-3110867416dpl:GroupUndertakingscore:ListedExchangeTraded2022-08-012023-07-3110867416core:ListedExchangeTraded2022-08-012023-07-3110867416dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-08-012023-07-3110867416core:UnlistedNon-exchangeTraded2022-08-012023-07-3110867416core:NetGoodwill2024-07-3110867416core:IntangibleAssetsOtherThanGoodwill2024-07-3110867416core:LandBuildings2024-07-3110867416core:PlantMachinery2024-07-3110867416core:Vehicles2024-07-3110867416core:FurnitureFittings2024-07-3110867416core:OfficeEquipment2024-07-3110867416core:AfterOneYear2024-07-3110867416core:WithinOneYear2024-07-3110867416core:ListedExchangeTraded2024-07-3110867416core:UnlistedNon-exchangeTraded2024-07-3110867416core:ShareCapital2024-07-3110867416core:SharePremium2024-07-3110867416core:RevaluationReserve2024-07-3110867416core:OtherReservesSubtotal2024-07-3110867416core:RetainedEarningsAccumulatedLosses2024-07-3110867416core:NetGoodwill2023-07-3110867416core:IntangibleAssetsOtherThanGoodwill2023-07-3110867416core:LandBuildings2023-07-3110867416core:PlantMachinery2023-07-3110867416core:Vehicles2023-07-3110867416core:FurnitureFittings2023-07-3110867416core:OfficeEquipment2023-07-3110867416core:AfterOneYear2023-07-3110867416core:WithinOneYear2023-07-3110867416core:ListedExchangeTraded2023-07-3110867416core:UnlistedNon-exchangeTraded2023-07-3110867416core:ShareCapital2023-07-3110867416core:SharePremium2023-07-3110867416core:RevaluationReserve2023-07-3110867416core:OtherReservesSubtotal2023-07-3110867416core:RetainedEarningsAccumulatedLosses2023-07-3110867416core:NetGoodwill2022-08-0110867416core:IntangibleAssetsOtherThanGoodwill2022-08-0110867416core:LandBuildings2022-08-0110867416core:PlantMachinery2022-08-0110867416core:Vehicles2022-08-0110867416core:FurnitureFittings2022-08-0110867416core:OfficeEquipment2022-08-0110867416core:AfterOneYear2022-08-0110867416core:WithinOneYear2022-08-0110867416core:ListedExchangeTraded2022-08-0110867416core:UnlistedNon-exchangeTraded2022-08-0110867416core:ShareCapital2022-08-0110867416core:SharePremium2022-08-0110867416core:RevaluationReserve2022-08-0110867416core:OtherReservesSubtotal2022-08-0110867416core:RetainedEarningsAccumulatedLosses2022-08-0110867416core:AfterOneYear2023-08-012024-07-3110867416core:WithinOneYear2023-08-012024-07-3110867416core:Non-currentFinancialInstrumentscore:CostValuation2023-08-012024-07-3110867416core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-012024-07-3110867416core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-012024-07-3110867416core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-012024-07-3110867416core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-012024-07-3110867416core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-012024-07-3110867416core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-012024-07-3110867416core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-012024-07-3110867416core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-012024-07-3110867416core:Non-currentFinancialInstrumentscore:CostValuation2024-07-3110867416core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-07-3110867416core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-07-3110867416core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-07-3110867416core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-07-3110867416core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-07-3110867416core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-07-3110867416core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-07-3110867416core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-07-3110867416core:Non-currentFinancialInstrumentscore:CostValuation2023-07-3110867416core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-07-3110867416core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-07-3110867416core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-07-3110867416core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-07-3110867416core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-07-3110867416core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-07-3110867416core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-07-3110867416core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-07-3110867416bus:Director12023-08-012024-07-3110867416bus:Director22023-08-012024-07-3110867416core:FurnitureFittingsToolsEquipment2023-07-3110867416core:FurnitureFittingsToolsEquipment2023-08-012024-07-3110867416core:FurnitureFittingsToolsEquipment2024-07-31

PHARMAMEDICAL LTD

Registered Number
10867416
(England and Wales)

Unaudited Financial Statements for the Year ended
31 July 2024

PHARMAMEDICAL LTD
Company Information
for the year from 1 August 2023 to 31 July 2024

Directors

AKBARIAN TEFAGHI, Niloufar
SALEHI, Parham

Registered Address

186 South Ealing Road
London
W5 4RJ

Registered Number

10867416 (England and Wales)
PHARMAMEDICAL LTD
Balance Sheet as at
31 July 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Intangible assets3200,950253,450
Tangible assets485,52798,860
286,477352,310
Current assets
Stocks526,47529,370
Debtors6382,584255,734
Cash at bank and on hand171,386163,529
580,445448,633
Creditors amounts falling due within one year8(480,525)(402,675)
Net current assets (liabilities)99,92045,958
Total assets less current liabilities386,397398,268
Creditors amounts falling due after one year9(225,171)(245,451)
Net assets161,226152,817
Capital and reserves
Called up share capital100100
Profit and loss account161,126152,717
Shareholders' funds161,226152,817
The financial statements were approved and authorised for issue by the Board of Directors on 26 March 2025, and are signed on its behalf by:
SALEHI, Parham
Director
Registered Company No. 10867416
PHARMAMEDICAL LTD
Notes to the Financial Statements
for the year ended 31 July 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Intangible assets
Goodwill, being the amount paid in connection with the acquisition of a business in 2018, is being amortised evenly over its estimated useful life of ten years.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Land and buildings25
Fixtures and fittings25
Vehicles25
Office Equipment25
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
Stocks and work in progress
Inventories are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
2.Average number of employees

20242023
Average number of employees during the year1311
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 August 23525,000525,000
At 31 July 24525,000525,000
Amortisation and impairment
At 01 August 23271,550271,550
Charge for year52,50052,500
At 31 July 24324,050324,050
Net book value
At 31 July 24200,950200,950
At 31 July 23253,450253,450
4.Tangible fixed assets

Land & buildings

Vehicles

Fixtures & fittings

Office Equipment

Total

£££££
Cost or valuation
At 01 August 2385,69452,8529,58169,608217,735
Additions-8,8009504,07013,820
At 31 July 2485,69461,65210,53173,678231,555
Depreciation and impairment
At 01 August 2352,72814,0393,12848,980118,875
Charge for year8,24211,7201,6675,52427,153
At 31 July 2460,97025,7594,79554,504146,028
Net book value
At 31 July 2424,72435,8935,73619,17485,527
At 31 July 2332,96638,8136,45320,62898,860
5.Stocks

2024

2023

££
Finished goods26,47529,370
Total26,47529,370
6.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables242,934193,500
Amounts owed by group undertakings49,2506,000
Other debtors84,58555,227
Prepayments and accrued income5,8151,007
Total382,584255,734
7.Current asset investments
8.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables219,888183,050
Bank borrowings and overdrafts44,11644,116
Taxation and social security67,70836,123
Payments received on account116,77487,640
Other creditors31,64151,746
Accrued liabilities and deferred income398-
Total480,525402,675
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
9.Creditors: amounts due after one year

2024

2023

££
Bank borrowings and overdrafts225,171245,451
Total225,171245,451
10.Related party transactions
At the year end, Brentham Ltd owed £44,900 (2023: £15,900), HRM London Ltd owed £17,940 (2023:17,940) and Betapharma Ltd owed £49,250 (2023: 6,000) to the company. The companies are related as Mr. Parham Salehi is also the director of these companies.